RecruitingNCT06771193

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy

Sponsor

MSD Italia S.r.l.

Enrollment

200 participants

Start Date

Dec 17, 2024

Study Type

OBSERVATIONAL

Conditions

Cervical Cancer Locally Advanced Cervical Cancer Recurrent Cervical Cancer Metastatic Cervical Cancer

Summary

Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study (no experimental treatment) describing the real-world characteristics and treatment patterns of women in Italy with locally advanced, recurrent, or metastatic cervical cancer who received care between 2018 and 2021. The goal is to better understand how this cancer is managed outside of clinical trials. **You may be eligible if...** - You are 18 or older with a diagnosis of cervical cancer - Your cancer was at a locally advanced stage (not suitable for surgery) or had recurred or spread - You received treatment between January 2018 and December 2021 - You have signed informed consent **You may NOT be eligible if...** - You participated in a pharmacological clinical trial for the treatment of your advanced cervical cancer - You received pembrolizumab, olaparib, lenvatinib, or drugs in those classes Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(11)

Oncologia Medica Policlinico Sant'Orsola Malpighi

Bologna, Bologna, Italy

Ginecologia ed Ostetricia A.O. Cannizzaro

Catania, Catania, Italy

Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino

Genova, Genova, Italy

Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele

Milan, Milano, Italy

Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X

Milan, Milano, Italy

Oncologia A.O.U. di Modena - Policlinico

Modena, Modena, Italy

U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale

Naples, Napoli, Italy

UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli

Naples, Napoli, Italy

IRCCS Centro di Riferimento Oncologico (CRO)

Aviano, Pordenone, Italy

U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli

Roma, Roma, Italy

UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima

Mestre, Venezia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06771193

Related Trials

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT0721670387 locations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180240 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671204 locations

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations